These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 34789492)

  • 21. Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative.
    Treadwell MJ; Du L; Bhasin N; Marsh AM; Wun T; Bender MA; Wong TE; Crook N; Chung JH; Norman S; Camilo N; Cavazos J; Nugent D
    Front Genet; 2022; 13():921432. PubMed ID: 36092883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care.
    Kanter J; Gibson R; Lawrence RH; Smeltzer MP; Pugh NL; Glassberg J; Masese RV; King AA; Calhoun C; Hankins JS; Treadwell M
    JAMA Netw Open; 2020 May; 3(5):e206016. PubMed ID: 32469413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sickle cell anaemia control mission: Implementation of a comprehensive care model in Anuppur, Madhya Pradesh.
    ;
    Indian J Med Res; 2024 Mar & Apr; 159(3 & 4):339-346. PubMed ID: 39361798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specifying sickle cell disease interventions: a study protocol of the Sickle Cell Disease Implementation Consortium (SCDIC).
    Baumann AA; Belle SH; James A; King AA;
    BMC Health Serv Res; 2018 Jun; 18(1):500. PubMed ID: 29945631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium.
    Masese RV; Bulgin D; Knisely MR; Preiss L; Stevenson E; Hankins JS; Treadwell MJ; King AA; Gordeuk VR; Kanter J; Gibson R; Glassberg JA; Tanabe P; Shah N;
    PLoS One; 2021; 16(10):e0258638. PubMed ID: 34714833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspectives of individuals with sickle cell disease on barriers to care.
    Phillips S; Chen Y; Masese R; Noisette L; Jordan K; Jacobs S; Hsu LL; Melvin CL; Treadwell M; Shah N; Tanabe P; Kanter J
    PLoS One; 2022; 17(3):e0265342. PubMed ID: 35320302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Awareness and Use of the Sickle Cell Disease Toolbox by Primary Care Providers in North Carolina.
    Ibemere SO; Tanabe P; Bonnabeau E; Rains G; Eason K; Earls MF; Shah N
    J Prim Care Community Health; 2021; 12():21501327211049050. PubMed ID: 34632830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
    Madden NA; Jones GL; Kalpatthi R; Woods G
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Process and strategies for patient engagement and outreach in the Sickle Cell Disease (SCD) community to promote clinical trial participation.
    Byrnes C; Botello-Harbaum M; Clemons T; Bailey L; Valdes KM; Coleman-Cowger VH
    J Natl Med Assoc; 2022 Apr; 114(2):211-217. PubMed ID: 35093266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS), a focus group and decision support tool development project.
    Tanabe P; Reddin C; Thornton VL; Todd KH; Wun T; Lyons JS
    Acad Emerg Med; 2010 Aug; 17(8):848-58. PubMed ID: 20670322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telehealth acceptability and opioid prescribing patterns of providers of painful chronic diseases during the COVID-19 pandemic: A survey of sickle cell providers.
    Kenney MO; Becerra B; Beatty SA; Smith WR
    J Opioid Manag; 2021; 17(6):489-497. PubMed ID: 34904697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding caregiver burden with accessing sickle cell care in the Midwest and their perspective on telemedicine.
    Jacob SA; Bouck J; Daas R; Jackson MD; LaMotte JE; Carroll AE
    BMC Health Serv Res; 2023 May; 23(1):500. PubMed ID: 37198614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric residents' perceived barriers to opioid use in sickle cell disease pain management.
    Fearon A; Marsh A; Kim J; Treadwell M
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27535. PubMed ID: 30387290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Pain is Subjective": A Mixed-Methods Study of Provider Attitudes and Practices Regarding Pain Management in Sickle Cell Disease Across Three Countries.
    Stewart KA; Parshad-Asnani M; Wonkam A; Bollinger J; Ngo Bitoungui V; Wonkam-Tingang E; Powell J; Desronvil K; Benson KRK; Clark A; Katz M; Martin B; Peterseim C; Williams C; Young N; Shah N; Tanabe P; Babyak M; Royal CDM
    J Pain Symptom Manage; 2021 Mar; 61(3):474-487. PubMed ID: 32889040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease.
    Harris KM; Preiss L; Varughese T; Bauer A; Calhoun CL; Treadwell M; Masese R; Hankins JS; Hussain FA; Glassberg J; Melvin CL; Gibson R; King AA;
    JAMA Netw Open; 2023 May; 6(5):e2314070. PubMed ID: 37200033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.
    Mulaku M; Opiyo N; Karumbi J; Kitonyi G; Thoithi G; English M
    Arch Dis Child; 2013 Nov; 98(11):908-14. PubMed ID: 23995076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Knowledge and practices of sickle cell disease among healthcare providers in Kinshasa, Democratic Republic of the Congo.
    Ngonde AM; Fina JL; Burgueno E; Lukanu PN
    Afr J Prim Health Care Fam Med; 2024 Feb; 16(1):e1-e8. PubMed ID: 38426772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
    Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
    Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dissemination of Evidence-Based Recommendations for Sickle Cell Disease to Primary Care and Emergency Department Providers in North Carolina: A Cost Benefit Analysis.
    Tanabe P; Blewer AL; Bonnabeau E; Bosworth HB; Clayton DH; Crego N; Earls MF; Eason K; Forlines G; Rains G; Young M; Shah N
    J Health Econ Outcomes Res; 2021 Apr; 8(1):18-28. PubMed ID: 33829067
    [No Abstract]   [Full Text] [Related]  

  • 40. Not being heard: barriers to high quality unplanned hospital care during young people's transition to adult services - evidence from 'this sickle cell life' research.
    Renedo A; Miles S; Chakravorty S; Leigh A; Telfer P; Warner JO; Marston C
    BMC Health Serv Res; 2019 Nov; 19(1):876. PubMed ID: 31752858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.